Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG Performance Status range of 0-2~* Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.~* May be systemic naïve or received up to two previous systemic treatment regimens for metastatic melanoma.~* Must be able to undergo MRI and have at least one measurable intracranial lesion for which specific criteria have to be met.~Exclusion Criteria:~* Prior treatment with any BRAF inhibitor or any mitogen-activated protein/extracellular signal-regulated kinase inhibitor.~* Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without delayed toxicity within treatment specific timeframe.~* Treatment with stereotactic radiosurgery or treatment with whole-brain radiation within treatment specific timeframe.~* Any presence of leptomeningeal disease or any parenchymal brain metastasis~* History of another malignancy, some exceptions may apply.~* A history or evidence of cardiovascular risk- specific criteria have to be met~* A history or current evidence/risk of retinal vein occlusion or retinal pigment epithelial detachment - specific criteria have to be met.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
- Cohort B (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- Cohort C (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- Cohort D (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).